Compare AbbVie Inc (ABBV) vs International Business Machines Corp (IBM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs International Business Machines Corp — how do they compare? AbbVie Inc trades at $253.61 (market cap $449.91B), while International Business Machines Corp trades at $302 (market cap $287.73B). The key difference: AbbVie Inc is the larger of the two by market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | IBM | |
|---|---|---|
Market Cap | $449.91B | $287.73B |
Sector | Health | Technology |
52-Week High | $261.07 | $329.23 |
52-Week Low | $184.85 | $214.64 |
Enterprise Value | $513.38B | $345.75B |
Dividend Yield | 2.72% | 2.21% |
Volume | — | 4,481,527 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
IBM's stock trades at $306.13, up 5.74% today, and is near its consensus price target of $308.14. The technical outlook is bullish with strong moving average signals, though the 6-day RSI indicates overbought conditions. Fundamentally, the company reported revenue of $67.54B in 2025 with a net income margin of 15.61%, and it has beaten earnings estimates for the last three quarters. Recent news highlights product launches in AI and quantum computing.
The outlook is positive with continued earnings momentum and strategic focus on high-growth areas like AI and hybrid cloud. Key risks include competitive pressures in technology and execution challenges in innovation. Analyst sentiment is mixed but leans bullish, with 47% buy ratings. The stock offers a dividend yield supported by strong cash flow from operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →
